Novel CRISPR-mediated
genome editing platformto develop safe, efficient and durable cures for genetic disease

SCRIPT Biosciences was founded in 2020 with the goal of developing potentially curative therapies for rare genetic disorders using our proprietary gene-editing platform

Our lead platform technology, CasPlus uses CRISPR based constructs to efficiently edit diverse mutation types responsible for the majority of monogenetic disorders

CasPlus has wide applicability and superior editing efficiency compared to existing technologies with the ability to produce 1 -3 base pair insertions in a predictable and template-free approach and supported by encouraging pre-clinical data

Multiple patents have been filed or are under development. Research and clinical development are led by recognized world leaders.

The CasPlus Platform is Designed for Predictable and Template-Free Gene Editing

Site-specific double-strand break

Precise 1 to 3 base pair insertions

Indels created in a DNA repair template-free manner

Uniquely Differentiated Within the Gene Editing Landscape

CRISPR/Cas9

CasPlus

Double Strand Break

Controlled DNA Repair

Template-Free Editing

Favorable editing to indel ratios

Off Target Edits

CAREERS

We seek a Research Associate/Lab Manager to support our therapeutic gene editing discovery efforts using the CasPlus platform.

Job description

The SCRIPT Biosciences Team

Script Management

Scientific Team

Anil Namboodiripad, Ph.D.
CEO

Patricia Tolete

Director Operations

Ravi Iyer, Ph.D.
‍
CSO

Script Management

Scientific Team

Menggui Huang, Ph.D.
Principal Scientist

Ursula Andréo, Ph.D.
Principal Scientist

Board of Directors

Chengzu Long, Ph.D.

Principal Investigator, NYU Gene Editing

Orrin Devinsky, M.D.

Professor & Director,
NYU Comprehensive Epilepsy Center

Glenn Fishman, M.D.

Professor & Director, NYU Division of Cardiology

Michael Jasulavic, MS

MiaMed
(acquired by Amicus Therapeutics)

Scientific Advisory Board

Wendy Chung, M.D.

National Academy
of Medicine
Association of American Physicians

Paul Modrich, Ph.D.

National Academy
of Sciences
2015 Nobel Prize
in Chemistry

Darren Monckton, Ph.D.

Professor of Human
Genetics

News, Publications, Materials

May 17, 2022

The CasPlus Gene Editing Platform Technology can Correct Mutations Associated with Duchenne's Muscular Dystrophy and Cystic Fibrosis with High Efficiency and Exceptionally Low Rates of On-Target DNA Damages.

Read Mode